Last update 20 Jun 2024

PIT-565

Overview

Basic Info

Drug Type
Trispecific T-cell engager (TriTE)
Synonyms
PIT565
Target
CD19 x CD2 x CD3
Mechanism
CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD2 inhibitors(T-cell surface antigen CD2 inhibitors), CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors)
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [2]
Active Indication
Systemic Lupus ErythematosusB-Cell LymphomaPre B-cell acute lymphoblastic leukemia
Inactive Indication-
Originator Organization
Novartis Pharmaceuticals Corp.
Active Organization
Novartis Pharmaceuticals Corp.
Inactive Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-

Related

2
Clinical Trials associated with PIT-565
NCT06335979 / Not yet recruitingPhase 1
A Phase Ib, Open-label, Ascending Dose Study With Step-up Doses to Assess Safety, Tolerability, and Pharmacokinetics of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).
NCT05397496 / RecruitingPhase 1
A Phase I, Open-label, Multi-center Study of PIT565 in Patients With Relapsed and/or Refractory B-cell Malignancies
100 Clinical Results associated with PIT-565
Login to view more data
100 Translational Medicine associated with PIT-565
Login to view more data
100 Patents (Medical) associated with PIT-565
Login to view more data
100 Deals associated with PIT-565
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Systemic Lupus ErythematosusPhase 1-
Novartis Pharmaceuticals Corp.
18 Nov 2024
B-Cell LymphomaPhase 1
US
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
JP
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
BE
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
FR
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
IL
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
IT
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
SG
Novartis Pharmaceuticals Corp.
03 Oct 2022
B-Cell LymphomaPhase 1
ES
Novartis Pharmaceuticals Corp.
03 Oct 2022
Pre B-cell acute lymphoblastic leukemiaPhase 1
US
Novartis Pharmaceuticals Corp.
03 Oct 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free